RxDoctor Payments Data

Peter Kim, MD

Gastroenterology · New York, NYNPI 1235157017

Payments from drug & device makers

$13,090in general payments, 2019–2025

Across 225 payments — averaging $58.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$8K
  • AbbVie$2K
  • Johnson & Johnson$587
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$462
  • Takeda Pharmaceuticals U.S.A., Inc.$426
  • QOL Medical, LLC$303
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$6,36049%
  • Travel & lodging$1,0798%
  • Food & beverage$5,61743%
  • Education$340%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,090 in reported general payments places this provider in the 75th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$96,245
Medicare patients
288
Services billed
1,566

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase30$68,869
XifaxanRifaximin22$48,864
LinzessLinaclotide65$39,472
Mesalamine28$6,999
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates110$6,766
Dexlansoprazole DrDexlansoprazole18$5,961
Mesalamine ErMesalamine17$5,569
Omeprazole223$2,359
Pantoprazole Sodium201$2,224
SutabSod Sulf/Pot Chloride/Mag Sulf13$2,081
Lubiprostone18$1,760
Budesonide EcBudesonide11$1,131
Esomeprazole Magnesium30$622
Famotidine50$350
Hydrocortisone11$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,628$108,34195 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$462$48,86422 claims
Braintree Laboratories, Inc.Sutab$152$2,08113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →